ZURICH: Novartis AG is buying US biotechnology company The Medicines Co for about US$9.7bil, the Swiss drugmaker said, as it seeks to expand its portfolio of medicines against cardiovascular disease.
Novartis is paying US$85 per share in cash, about a 24% premium over The Medicines Co’s closing share price of US$68.55 last Friday.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
